OnCore Login

Return to Trial Database

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status

Currently Enrolling

Cancer Type(s)

Breast

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Publications

Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA)
  • C Shen, Y Abdou, L Chen, X Tan, G Gupta, F Lynce, M Lobbous, E Stringer-Reasor, C Anders

Trial Locations

All sites in which the trial HCRN-BRE18-360 being conducted in.
Cleveland Clinic Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Memorial Breast Cancer Center at Memorial Regional Hospital
Memorial Sloan Kettering Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278